Alnylam Pharmaceuticals, Inc. – NASDAQ:ALNY
Alnylam Pharmaceuticals stock price today
$449.12
+211.15
+88.73%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 8 hours
Alnylam Pharmaceuticals stock price monthly change
-8.65%
month
Alnylam Pharmaceuticals stock price quarterly change
-8.65%
quarter
Alnylam Pharmaceuticals stock price yearly change
+21.06%
year
Alnylam Pharmaceuticals key metrics
Market Cap | 30.89B |
Enterprise value | 25.45B |
P/E | -20.76 |
EV/Sales | 24.53 |
EV/EBITDA | -28.74 |
Price/Sales | 24.09 |
Price/Book | -158.00 |
PEG ratio | 0.71 |
EPS | -2.65 |
Revenue | 2.00B |
EBITDA | -195.38M |
Income | -332.07M |
Revenue Q/Q | 54.82% |
Revenue Y/Y | 75.20% |
Profit margin | -109.04% |
Oper. margin | -75.68% |
Gross margin | 83.73% |
EBIT margin | -75.68% |
EBITDA margin | -9.75% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAlnylam Pharmaceuticals stock price history
Alnylam Pharmaceuticals stock forecast
Alnylam Pharmaceuticals financial statements
Average Price Target
$329.83
Potential downside: -26.56%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 318.75M | -276.02M | -86.59% |
|---|---|---|---|
| Sep 2023 | 750.53M | 147.75M | 19.69% |
| Dec 2023 | 439.71M | -137.87M | -31.35% |
| Mar 2024 | 494.33M | -65.93M | -13.34% |
| 2024-02-15 | -1.2 | -1.1 |
|---|
| Jun 2023 | 3402396000 | 3.81B | 112% |
|---|---|---|---|
| Sep 2023 | 3839073000 | 4.00B | 104.32% |
| Dec 2023 | 3829880000 | 4.05B | 105.76% |
| Mar 2024 | 3824386000 | 4.04B | 105.73% |
| Jun 2023 | -58.98M | -8.71M | 53.39M |
|---|---|---|---|
| Sep 2023 | 359.41M | -10.76M | 33.13M |
| Dec 2023 | -29.79M | -240.65M | 39.22M |
| Mar 2024 | -81.51M | -67.62M | 28.91M |
Alnylam Pharmaceuticals alternative data
| Aug 2023 | 2,002 |
|---|---|
| Sep 2023 | 2,002 |
| Oct 2023 | 2,002 |
| Nov 2023 | 2,002 |
| Dec 2023 | 2,002 |
| Jan 2024 | 2,002 |
| Feb 2024 | 2,002 |
| Mar 2024 | 2,100 |
| Apr 2024 | 2,100 |
| May 2024 | 2,100 |
| Jun 2024 | 2,100 |
| Jul 2024 | 2,100 |
Alnylam Pharmaceuticals other data
94.77%
+1.20%
of ALNY is owned by hedge funds
417
+1
112.25M
+781.37K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 0 | 46855 |
| May 2024 | 0 | 21700 |
| Jun 2024 | 0 | 55762 |
| Jul 2024 | 0 | 7093 |
| Aug 2024 | 0 | 72423 |
| Nov 2024 | 0 | 13052 |
| Dec 2024 | 0 | 1752 |
| Patent |
|---|
Application METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12) Filling date: 28 Sep 2021 Issue date: 25 Aug 2022 |
Application Filling date: 10 Aug 2021 Issue date: 18 Aug 2022 |
Application Filling date: 26 Oct 2021 Issue date: 11 Aug 2022 |
Application Filling date: 14 Sep 2021 Issue date: 11 Aug 2022 |
Grant Utility: Modified RNAi agents Filling date: 16 Apr 2020 Issue date: 9 Aug 2022 |
Application Filling date: 14 Sep 2021 Issue date: 4 Aug 2022 |
Grant Filling date: 12 Jan 2022 Issue date: 2 Aug 2022 |
Grant Utility: Modified double-stranded RNA agents Filling date: 25 Nov 2019 Issue date: 2 Aug 2022 |
Application Filling date: 6 Apr 2022 Issue date: 28 Jul 2022 |
Application Filling date: 31 Jan 2022 Issue date: 21 Jul 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 2 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 15 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. John M. Maraganore M.D., Ph.D. (1963) Chief Executive Officer & Executive Director | $2,070,000 |
Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB (1963) Pres, Chief Operating Officer & Director | $1,240,000 |
| Dr. Akshay K. Vaishnaw (1963) Pres of R&D | $1,090,000 |
Mr. Jeffrey V. Poulton M.B.A. (1968) Chief Financial Officer & Executive Vice President | $893,470 |
Mr. Michael W. Bonney B.A. (1958) Executive Chairman | $106,250 |
Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)
Alnylam Pharmaceuticals: Commercialization And Early-Stage Studies Are Likely To Drive 2025
Biotech Stocks 2024 Second Half Outlook - Buy Biotechs
HELIOS-B Shines Bright And Gives Alnylam Pharmaceuticals Another Blockbuster
The 'Undercovered' Dozen From June 1-6
Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation
Roche Is Joining The Obesity Party But Questions Remain
Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause
Regeneron's Push Into Obesity, Q4 2023 Earnings Review
-
What's the price of Alnylam Pharmaceuticals stock today?
One share of Alnylam Pharmaceuticals stock can currently be purchased for approximately $449.12.
-
When is Alnylam Pharmaceuticals's next earnings date?
Unfortunately, Alnylam Pharmaceuticals's (ALNY) next earnings date is currently unknown.
-
Does Alnylam Pharmaceuticals pay dividends?
No, Alnylam Pharmaceuticals does not pay dividends.
-
How much money does Alnylam Pharmaceuticals make?
Alnylam Pharmaceuticals has a market capitalization of 30.89B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 76.23% to 1.83B US dollars. Alnylam Pharmaceuticals made a loss 440.24M US dollars in net income (profit) last year or -$1.1 on an earnings per share basis.
-
What is Alnylam Pharmaceuticals's stock symbol?
Alnylam Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "ALNY".
-
What is Alnylam Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Alnylam Pharmaceuticals?
Shares of Alnylam Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Alnylam Pharmaceuticals's key executives?
Alnylam Pharmaceuticals's management team includes the following people:
- Dr. John M. Maraganore M.D., Ph.D. Chief Executive Officer & Executive Director(age: 62, pay: $2,070,000)
- Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB Pres, Chief Operating Officer & Director(age: 62, pay: $1,240,000)
- Dr. Akshay K. Vaishnaw Pres of R&D(age: 62, pay: $1,090,000)
- Mr. Jeffrey V. Poulton M.B.A. Chief Financial Officer & Executive Vice President(age: 57, pay: $893,470)
- Mr. Michael W. Bonney B.A. Executive Chairman(age: 67, pay: $106,250)
-
How many employees does Alnylam Pharmaceuticals have?
As Jul 2024, Alnylam Pharmaceuticals employs 2,100 workers.
-
When Alnylam Pharmaceuticals went public?
Alnylam Pharmaceuticals, Inc. is publicly traded company for more then 21 years since IPO on 1 Jun 2004.
-
What is Alnylam Pharmaceuticals's official website?
The official website for Alnylam Pharmaceuticals is alnylam.com.
-
Where are Alnylam Pharmaceuticals's headquarters?
Alnylam Pharmaceuticals is headquartered at 675 West Kendall Street, Cambridge, MA.
-
How can i contact Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals's mailing address is 675 West Kendall Street, Cambridge, MA and company can be reached via phone at +61 75518200.
-
What is Alnylam Pharmaceuticals stock forecast & price target?
Based on 5 Wall Street analysts` predicted price targets for Alnylam Pharmaceuticals in the last 12 months, the avarage price target is $329.83. The average price target represents a -26.56% change from the last price of $449.12.
Alnylam Pharmaceuticals company profile:
Alnylam Pharmaceuticals, Inc.
alnylam.comExchange:
NASDAQ
Full time employees:
2,100
Industry:
Biotechnology
Sector:
Healthcare
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
675 West Kendall Street
Cambridge, MA 02142
Cambridge, MA 02142
CIK: 0001178670
ISIN: US02043Q1076
CUSIP: 02043Q107
